A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer
Abstract Angiogenesis plays a key role in tumor development and αvβ3 integrin are overexpressed on the endothelial cell surface of newly forming vessels. 18F-Alfatide has favorable properties for αvβ3 integrin targeting and showed potential for imaging angiogenesis with Positron Emission Tomography...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/174eb3ab29de41a8bbc5980008899428 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:174eb3ab29de41a8bbc5980008899428 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:174eb3ab29de41a8bbc59800088994282021-12-02T16:06:46ZA Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer10.1038/s41598-017-03296-62045-2322https://doaj.org/article/174eb3ab29de41a8bbc59800088994282017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-03296-6https://doaj.org/toc/2045-2322Abstract Angiogenesis plays a key role in tumor development and αvβ3 integrin are overexpressed on the endothelial cell surface of newly forming vessels. 18F-Alfatide has favorable properties for αvβ3 integrin targeting and showed potential for imaging angiogenesis with Positron Emission Tomography (PET)/computed tomography (CT). In this study, 13 patients with non-small cell lung cancer (NSCLC) who underwent 18F-Alfatide PET/CT before surgery were enrolled. The uptake of all dissected lymph nodes (LNs) of 18F-Alfatide were assessed visually and analyzed with a maximum and mean standard uptake value (SUVmax, SUVmean) and SUV ratios. LN metastases were pathologically confirmed and 20 of 196 LNs were malignant. All malignant LNs were successfully visualized on 18F-Alfatide PET/CT in patients and the sensitivity, specificity and accuracy was 100.0%, 94.9% and 95.4%, respectively. SUVmax, SUVmean and SUV ratios in malignant LNs were significantly higher than in benign LNs for NSCLC patients (P < 0.001). The same result was observed in patients with adenocarcinoma and squamous cell carcinoma (P < 0.001). The 18F-Alfatide parameter shows high sensitivity (83.9–100%), specificity (78.6–96.7%) and accuracy (81.7–96.9%) according to thresholds calculated from receiver operating characteristic curve. Our results suggest that 18F-Alfatide PET/CT is valuable in the diagnosis of metastatic LNs for NSCLC patients.Yue ZhouSong GaoYong HuangJinsong ZhengYinjun DongBaijiang ZhangShuqiang ZhaoHong LuZhibo LiuJinming YuShuanghu YuanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-7 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Yue Zhou Song Gao Yong Huang Jinsong Zheng Yinjun Dong Baijiang Zhang Shuqiang Zhao Hong Lu Zhibo Liu Jinming Yu Shuanghu Yuan A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer |
| description |
Abstract Angiogenesis plays a key role in tumor development and αvβ3 integrin are overexpressed on the endothelial cell surface of newly forming vessels. 18F-Alfatide has favorable properties for αvβ3 integrin targeting and showed potential for imaging angiogenesis with Positron Emission Tomography (PET)/computed tomography (CT). In this study, 13 patients with non-small cell lung cancer (NSCLC) who underwent 18F-Alfatide PET/CT before surgery were enrolled. The uptake of all dissected lymph nodes (LNs) of 18F-Alfatide were assessed visually and analyzed with a maximum and mean standard uptake value (SUVmax, SUVmean) and SUV ratios. LN metastases were pathologically confirmed and 20 of 196 LNs were malignant. All malignant LNs were successfully visualized on 18F-Alfatide PET/CT in patients and the sensitivity, specificity and accuracy was 100.0%, 94.9% and 95.4%, respectively. SUVmax, SUVmean and SUV ratios in malignant LNs were significantly higher than in benign LNs for NSCLC patients (P < 0.001). The same result was observed in patients with adenocarcinoma and squamous cell carcinoma (P < 0.001). The 18F-Alfatide parameter shows high sensitivity (83.9–100%), specificity (78.6–96.7%) and accuracy (81.7–96.9%) according to thresholds calculated from receiver operating characteristic curve. Our results suggest that 18F-Alfatide PET/CT is valuable in the diagnosis of metastatic LNs for NSCLC patients. |
| format |
article |
| author |
Yue Zhou Song Gao Yong Huang Jinsong Zheng Yinjun Dong Baijiang Zhang Shuqiang Zhao Hong Lu Zhibo Liu Jinming Yu Shuanghu Yuan |
| author_facet |
Yue Zhou Song Gao Yong Huang Jinsong Zheng Yinjun Dong Baijiang Zhang Shuqiang Zhao Hong Lu Zhibo Liu Jinming Yu Shuanghu Yuan |
| author_sort |
Yue Zhou |
| title |
A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer |
| title_short |
A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer |
| title_full |
A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer |
| title_fullStr |
A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer |
| title_full_unstemmed |
A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer |
| title_sort |
pilot study of 18f-alfatide pet/ct imaging for detecting lymph node metastases in patients with non-small cell lung cancer |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/174eb3ab29de41a8bbc5980008899428 |
| work_keys_str_mv |
AT yuezhou apilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT songgao apilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT yonghuang apilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT jinsongzheng apilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT yinjundong apilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT baijiangzhang apilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT shuqiangzhao apilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT honglu apilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT zhiboliu apilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT jinmingyu apilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT shuanghuyuan apilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT yuezhou pilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT songgao pilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT yonghuang pilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT jinsongzheng pilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT yinjundong pilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT baijiangzhang pilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT shuqiangzhao pilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT honglu pilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT zhiboliu pilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT jinmingyu pilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer AT shuanghuyuan pilotstudyof18falfatidepetctimagingfordetectinglymphnodemetastasesinpatientswithnonsmallcelllungcancer |
| _version_ |
1718384825817104384 |